Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,062.01 +464.98 (+0.71%) CMC Crypto 200
1,403.85 -14.03 (-0.99%)
Biotech and drug stocks
7.48k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Biotech and drug stocks | -0.60% | - | - | - |
| ^GSPC | -0.04% | +2.54% | +23.18% | +5740.43% |
31 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 878.45 | -4.88 | -0.55% | 4:00 pm GMT-4 | 1.52M | 2.59M | 834.88B |
| NVO | Novo Nordisk A/S | 142.5 | +0.01 | +0.01% | 4:00 pm GMT-4 | 2.54M | 3.79M | 636.08B |
| JNJ | Johnson & Johnson | 145.54 | +0.09 | +0.06% | 4:00 pm GMT-4 | 4.04M | 7.52M | 350.27B |
| MRK | Merck & Co., Inc. | 129.48 | +0.11 | +0.09% | 4:00 pm GMT-4 | 3.49M | 7.53M | 327.95B |
| ABBV | AbbVie Inc. | 168.59 | +2.03 | +1.22% | 4:00 pm GMT-4 | 4.33M | 5.32M | 297.71B |
| AZN | AstraZeneca PLC | 79.59 | +0.06 | +0.08% | 4:00 pm GMT-4 | 1.93M | 5.03M | 246.77B |
| RHHBY | Roche Holding AG | 34.67 | +0.14 | +0.41% | 3:59 pm GMT-4 | 217.60k | 3.15M | 223.90B |
| NVS | Novartis AG | 105.72 | -0.30 | -0.28% | 4:00 pm GMT-4 | 2.09M | 1.53M | 216.83B |
| AMGN | Amgen Inc. | 298.62 | +0.12 | +0.04% | 4:00 pm GMT-4 | 1.41M | 2.48M | 160.19B |
| PFE | Pfizer Inc. | 27.53 | -0.12 | -0.43% | 4:00 pm GMT-4 | 24.23M | 38.10M | 156.00B |
| VRTX | Vertex Pharmaceuticals Incorporated | 480.73 | +1.70 | +0.35% | 4:00 pm GMT-4 | 640.79k | 1.07M | 124.05B |
| SNY | Sanofi | 46.25 | -1.28 | -2.69% | 4:00 pm GMT-4 | 3.80M | 2.18M | 118.92B |
| REGN | Regeneron Pharmaceuticals, Inc. | 1036.52 | +9.97 | +0.97% | 4:00 pm GMT-4 | 352.54k | 426.58k | 114.21B |
| GSK | GSK plc | 40.65 | -0.46 | -1.12% | 4:00 pm GMT-4 | 1.87M | 3.38M | 84.02B |
| BMY | Bristol-Myers Squibb Company | 41.2 | -0.28 | -0.68% | 4:00 pm GMT-4 | 14.27M | 13.70M | 83.52B |
| GILD | Gilead Sciences, Inc. | 65.06 | +2.27 | +3.62% | 4:00 pm GMT-4 | 9.32M | 6.91M | 81.05B |
| ZTS | Zoetis Inc. | 170.55 | -0.77 | -0.45% | 4:00 pm GMT-4 | 2.22M | 3.29M | 77.82B |
| DSNKY | Daiichi Sankyo Company, Limited | 34.33 | -1.19 | -3.35% | 3:59 pm GMT-4 | 1.12k | 206.05k | 65.97B |
| MRNA | Moderna, Inc. | 140.03 | -5.20 | -3.58% | 4:00 pm GMT-4 | 3.60M | 3.87M | 53.67B |
| TAK | Takeda Pharmaceutical Company Limited | 13.1 | +0.02 | +0.15% | 4:00 pm GMT-4 | 1.07M | 1.56M | 41.36B |
| HLN | Haleon plc | 8.39 | -0.09 | -1.06% | 4:00 pm GMT-4 | 2.54M | 6.73M | 38.31B |
| BIIB | Biogen Inc. | 231.69 | -2.15 | -0.92% | 4:00 pm GMT-4 | 747.83k | 1.15M | 33.73B |
| BAYRY | Bayer Aktiengesellschaft | 7.24 | -0.11 | -1.50% | 3:57 pm GMT-4 | 63.49k | 1.98M | 28.55B |
| ARGX | argenx SE | 387 | -1.34 | -0.35% | 4:00 pm GMT-4 | 194.28k | 263.27k | 23.04B |
| BNTX | BioNTech SE | 92.08 | -3.92 | -4.08% | 4:00 pm GMT-4 | 750.54k | 735.39k | 22.19B |
| ALNY | Alnylam Pharmaceuticals, Inc. | 160.39 | +0.34 | +0.21% | 4:00 pm GMT-4 | 621.07k | 545.11k | 20.29B |
| TEVA | Teva Pharmaceutical Industries Limited | 17.16 | -0.24 | -1.38% | 4:00 pm GMT-4 | 4.93M | 9.71M | 19.56B |
| ALPMY | Astellas Pharma Inc. | 9.46 | -0.13 | -1.36% | 3:47 pm GMT-4 | 11.18k | 370.23k | 17.05B |
| GMAB | Genmab A/S | 26.19 | -0.22 | -0.83% | 4:00 pm GMT-4 | 355.83k | 445.78k | 16.94B |
| RPRX | Royalty Pharma plc | 26.92 | -0.28 | -1.03% | 4:00 pm GMT-4 | 1.67M | 2.66M | 16.08B |
Motley FoolMounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
The company has too many weapons at its disposal.
GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi plus chemotherapy1 This Columvi combination could provide a much-needed off-the-shelf treatment option for people with transplant-ineligible R/R DLBCLData were featured in the congress Press Briefing and presented today in the Plenary Abstracts Session at EHA 2024 as a late-breaking oral presentatio
Business WireGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif., June 15, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from its Phase III STARGLO study of Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of
